Status: Recruiting
Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.
This is a Phase I/II interventional, open-label treatment study designed to evaluate the safety and efficacy of concomitant therapy with anti-CD19 CAR T-cells and Lenalidomide in adult patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who have been pretreated with Ibrutinib for 3 months prior to leukapheresis.
Participants needed: 24
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Vitebsk Regional Clinical Cancer CentreUpdated: Aug 13, 2026Locations: 1
Eligibility criteria
Documented CD19+ CLL or SLL [+9]
CLL patients with known or suspected transformed disease (i.e. Richter's transfo... [+9]